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Complement Factor D in Age-Related
Macular Degeneration
Chloe M. Stanton,1 John R.W. Yates,2 Anneke I. den Hollander,3 Johanna M. Seddon,4
Anand Swaroop,5 Dwight Stambolian,6 Sascha Fauser,7 Carel Hoyng,3 Yi Yu,4
Kanda Atsuhiro,5 Kari Branham,8 Mohammad Othman,8 Wei Chen,9 Elod Kortvely,10
Kevin Chalmers,1 Caroline Hayward,1 Anthony T. Moore,2 Baljean Dhillon,11
Marius Ueffing,10 and Alan F. Wright1
PURPOSE. To examine the role of complement factor D (CFD) in
age-related macular degeneration (AMD) by analysis of genetic
association, copy number variation, and plasma CFD concen-
trations.
METHODS. Single nucleotide polymorphisms (SNPs) in the CFD
gene were genotyped and the results analyzed by binary logis-
tic regression. CFD gene copy number was analyzed by gene
copy number assay. Plasma CFD was measured by an enzyme-
linked immunosorbent assay.
RESULTS. Genetic association was found between CFD gene
SNP rs3826945 and AMD (odds ratio 1.44; P 0.028) in a small
discovery case-control series (462 cases and 325 controls) and
replicated in a combined cohorts meta-analysis of 4765 cases
and 2693 controls, with an odds ratio of 1.11 (P 0.032), with
the association almost confined to females. Copy number vari-
ation in the CFD gene was identified in 13 out of 640 samples
examined but there was no difference in frequency between
AMD cases (1.3%) and controls (2.7%). Plasma CFD concentra-
tion was measured in 751 AMD cases and 474 controls and
found to be elevated in AMD cases (P  0.00025). The odds
ratio for those in the highest versus lowest quartile for plasma
CFD was 1.81. The difference in plasma CFD was again almost
confined to females.
CONCLUSIONS. CFD regulates activation of the alternative com-
plement pathway, which is implicated in AMD pathogenesis.
The authors found evidence for genetic association between a
CFD gene SNP and AMD and a significant increase in plasma
CFD concentration in AMD cases compared with controls,
consistent with a role for CFD in AMD pathogenesis. (Invest
Ophthalmol Vis Sci. 2011;52:8828–8834) DOI:10.1167/iovs.11-
7933
Complement factor D (CFD; also known as adipsin) is amember of the chymotrypsin family of serine proteases
and regulates a key step in the activation of the alternative
complement pathway.1,2 It is expressed in several tissues and
cell types, but the major source of plasma CFD in humans is
adipose tissue3 (http://www.cgl.ucsf.edu/cgi-bin/genentech/
genehub-gepis/), in which it is secreted by both mature adi-
pocytes and macrophages.4–7 Like other secreted serine pro-
teases, the N-terminal signal peptide is first cleaved in the
secretory pathway, leaving an inactive zymogen, proCFD.1,8
However, its subsequent maturation differs from other serine
proteases in two main ways. First, the five to six amino acid
N-terminal activation domain in humans is rapidly cleaved,
either within the secretary pathway or soon after its release
into plasma, leaving 99% of plasma CFD in the CFD rather
than proCFD form.9–11 Second, activation is thought to occur
subsequent to CFD formation as a result of a conformational
change which occurs when it binds C3bB, a complex of factor
B, magnesium ions, and complement component 3b (C3b).1,2,8
CFD becomes transiently active and is able to cleave factor B
within this complex into Ba and Bb fragments. This is widely
regarded as a rate limiting step in formation of the C3bBb
complex or C3 convertase, which amplifies the initial signal
and is crucial to activation of the alternative complement
pathway.1,4 CFD has a uniquely narrow substrate specificity,
only cleaving factor B. Plasma CFD concentrations are very low
(1–2 g/mL),12 the lowest of any complement protein, strik-
ingly lower than plasma C3 (1–2 mg/mL) or factor B (200g/
mL),13 so that it only ceases to be limiting at 9 to 10 times
higher concentrations.11
Age-related macular degeneration (AMD) is the most com-
mon cause of severe visual handicap in industrialized coun-
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tries.14 It is associated with the progressive deposition of ex-
tracellular material (drusen or basal deposits) between the
basal surface of the macular RPE and Bruch’s membrane.15 This
is thought to be associated with immune attack, leading to
dysfunction and eventual death of macular RPE cells (geo-
graphic atrophy; GA).16 In 5%–10% of affected subjects, cho-
roidal neovascularization (CNV) can lead to hemorrhage and
exudation within the macula, causing catastrophic loss of vi-
sion. The major risk factors in AMD include age, smoking, and
genetic influences.17 The latter include genetic variation in
genes influencing the alternative complement pathway such as
CFH, C2/BF, C3, and FI (reviewed in Refs. 16, 18). Other
genetic risk factors include variants influencing extracellular
matrix function, such as TIMP3, FBL6, and ARMS2 and genes
involved in lipid metabolism, such as APOE, LIPC, and
CETP.16,18–20
The strong association of AMD with genes encoding com-
ponents of the alternative complement pathway prompted us
to examine the role of genetic variation influencing CFD, in-
cluding copy number variation and plasma concentrations,
particularly because CFD has an important role in activation of
this pathway.
MATERIALS AND METHODS
Study Cohorts
The clinical and demographic features of the six case-control series are
summarized in Table 1.
Genotyping
Initially, only three SNPs were identified within the CFD gene
(rs1683564, rs3826945, rs1683563) one of which (rs16853564) was
not successfully genotyped. DNA was genotyped in two UK case-
control series (UK1, UK2) for two intronic CFD SNPs, rs3826945 and
rs1683563, using genotyping technology (TaqMan; Applied Biosys-
tems, Foster City, CA). All genotyping assays were pre-validated by the
supplier. Five-microliter reactions were set up in 384-well plates (Taq-
Man Universal PCR Master Mix, No AmpEraseUNG; Applied Biosys-
tems) with 7.5 ng DNA, 1 M of each primer, and 0.2 M of probe. The
thermal cycling reactions (95°C for 10 minutes, followed by 40 cycles
at 92°C for 15 seconds and 60°C for 1 minute) were run and analyzed
(7900HT Sequence Detection System; Applied Biosystems) with ge-
netic analysis software (Genotyper SDS system, version 2.2; Applied
Biosystems). As controls, each plate contained multiple blank wells
without DNA. Similarly, for the USA 2 (University of Pennsylvania) and
Dutch-German (Nijmegen) case-control series, assays (TaqMan; Ap-
plied Biosystems) were also used to genotype rs3826945 and
rs1683563. In the USA 3 series, SNPs rs3826945 and rs1683563 were
genotyped using a different assay (Sequenom iPLEX; Sequenom, San
Diego, CA), as described.21
In the USA 1 case-control series (University of Michigan), CFD SNPs
rs1683563 and rs3826945 were genotyped as follows. Primers were
designed and used to polymerase chain reaction (PCR) amplify the
amplicons for dye-termination Sanger sequencing. The primers for the
rs1683563 were: forward primer 5AGTGTGGCCTTCTCCGACAG and re-
verse primer 5AAATCTCTCCTGCTGCACTGA. Primers for rs3826945 were:
forward primer 5CACGTGTTAGACCCCCTCAC and reverse primer 5TG-
GAAGAGCAGGAATGAGGT. Standard PCR conditions were followed with
the use of polymerase (TaKaRa Ex Taq; Takara Bio Inc., Shiga, Japan) with
1 L of DNA (approximately 100 ng/L), and PCR conditions: melting
temperature 94°C for 2 minutes; 35 cycles at 94°C for 30 seconds;
annealing at 60°C for 30 seconds; extension at 72°C for 30 seconds;
followed by extension at 72°C for 7 minutes. PCR products were run
on 1.5% ethidium bromide agarose gels and viewed on a gel documen-
tation system (Kodak 440; Kodak, Rochester, NY). Aliquots of the PCR
products were submitted for sequencing at the University of Michigan
core facility.
Copy Number Variation Analysis
Copy number variation at the CFD locus was assessed using a copy
number assay (Hs01536182_cn; TaqMan; Applied Biosystems), run
simultaneously with a copy number reference assay (TaqMan; Applied
Biosystems) for RNAseP in a duplex real-time polymerase chain reac-
tion. The CFD probe was FAM-labeled and the endogenous control was
VIC-labeled. Ten-microliter reactions were set up in 384-well plates
(TaqMan Universal PCR Master Mix, No AmpEraseUNG; Applied Bio-
systems) with 10 ng genomic DNA, 1 M of each primer, and 0.2 M
of probe. The thermal cycling reactions (95°C for 10 minutes, followed
by 40 cycles at 92°C for 15 seconds and 60°C for 1 minute) were run
on a sequence detection system (7900HT Sequence Detection System;
TABLE 1. Cohort Characteristics
Cohort Status n % Grading %
Mean
Age (y) SD
Sex
Male % Female %
Scottish Control 347 41.0 78.0 8.5 152 43.8 199 57.3
Case 499 59.0 Late AMD 48.3 77.9 9.2 190 38.1 315 63.1
Total 846
English Control 421 32.1 75.6 7.7 171 40.6 232 55.1
Case 891 67.9 Late AMD 100.0 78.7 7.2 377 42.3 472 53.0
Total 1312
USA 1 Control 311 33.8 76.6 5.1 143 46.0 168 54.0
Case 608 66.2 Late AMD 85.9 79.3 7.3 222 36.5 386 63.5
Total 919
USA 2 Control 378 42.1 75.6 7.9 177 46.8 203 53.7
Case 520 57.9 Late AMD 100.0 80.0 8.5 206 39.6 314 60.4
Total 898
USA 3 Control 887 40.1 75.4 6.1 394 44.4 501 56.5
Case 1326 59.9 Late AMD 100.0 80.7 6.3 583 44.0 758 57.2
Total 2213
Dutch-German Control 562 31.9 72.7 6.6 245 43.6 314 55.9
Case 1201 68.1 Late AMD 91.3 75.9 8.2 456 38.0 744 61.9
Total 1763
Grading was performed by an ophthalmologist and refers to the worst eye. Controls were also examined. Late AMD includes cases of GA and
neovascular AMD (CNV). Grading was based on the Clinical Age-Related Maculopathy Grading System (CARMS).33 All cohorts were made up of
Caucasian individuals. The numbers shown in the main text refer to the number of individuals that were successfully genotyped for CFD SNPs.
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Applied Biosystems). Samples were analyzed in triplicate, and each
plate contained multiple “no template” control wells without DNA.
The relative copy number of CFD, normalized to the known copy
number of the RNAseP reference sequence, was calculated using
commercially available software (Copycaller v1.0; Applied Biosys-
tems).
Plasma Samples
Blood samples were collected in dipotassium EDTA-coated tubes.
Plasma was separated from blood cells by centrifugation within 3 hours
of collection and was frozen in aliquots at 80°C until use.
Measurement of CFD in Plasma by ELISA
Plasma CFD was measured using an ELISA development kit (DuoSet)
for human complement factor D (R&D Systems, Minneapolis, MN),
optimized for use in plasma. The kit was used as described by the
manufacturer; plasma samples were diluted 1 in 4000 for analysis. A
standard curve ranging from 0 to 2.5 ng/mL was included on each
plate, alongside three internal control plasma samples used to assess
interassay variability. The interassay coefficient of variation was below
10%. CFD was measured without prior knowledge of disease status for
each sample. AMD cases and control samples were included on each
plate assayed and all samples were measured in duplicate.
Statistical Analysis
Genotyping, copy number variation, and CFD ELISA data were main-
tained using statistical analysis and data management software (SPSS
version 17; SPSS Inc., Chicago, IL).
SNP genotyping was assessed for deviation from Hardy-Weinberg
equilibrium in AMD cases and controls using a 2 test. The association
of SNPs with AMD was tested using logistic regression analysis to
model the probability of disease occurrence, including known risk
factors—age, sex, and smoking history—as variables along with SNP
genotype in the analyses. Age was included as a continuous variable.
Sex and smoking history (ever/never) were considered as categorical
values. A P value of  0.05 was considered a significant association
with AMD, as correction for multiple testing was not necessary. Logis-
tic regression was also performed in individual and combined cohorts
stratified by sex. In these analyses, SNP genotype, age, and smoking
status were included as variables. Odds ratios (ORs) and 95% confi-
dence intervals (CIs) for association were also calculated. A Forest plot
for ORs and 95% CIs for each cohort was constructed with software
(GraphPad Prism 5; GraphPad Software Inc., La Jolla, CA).
Association of AMD with copy number variation (defined as either
deletion or duplication) at the CFD locus was evaluated using Fisher’s
exact test.
The Mann-Whitney U test was used to assess differences between
median values of CFD measured in plasma for AMD cases (GA, CNV,
and total AMD) and controls. Logistic regression, controlling for age (
65 years of age/65 to 80 years of age, and aged over 80 years), sex, and
smoking (ever/never), was performed to compare the first and fourth
quartiles of plasma CFD values in AMD cases and controls, and to
calculate ORs and 95% CIs. Body mass index (BMI;25, 25–29.9,30)
was included as a covariate in analysis of the UK 2 cohort.
RESULTS
Genetic Association between CFD Variants
and AMD
Initially we examined the association of AMD with SNPs within
the CFD gene. Only three common CFD SNPs (rs 3826945,
rs1683564, and rs1683563) with a minor allele frequency
10% in the CEPH Caucasian reference population were iden-
tified in HapMap. One of these, rs16853564, was not success-
fully genotyped. Other SNPs had lower minor allele frequen-
cies and so were unlikely to provide adequate power. The
Tagger-pairwise Tagging algorithm (http://hapmap.ncbi.nlm.
nih.gov/) identified rs3826945 and rs1683564 as tagging SNPs.
Rs3826945 and rs1683563 are in high linkage disequilibrium (LD)
(D’ 1), but not complete LD (r2 0.314), so both SNPs remain
informative. A dominant genotypic model and binary logistic
regression analysis was used, including sex, smoking, and SNP as
categorical variables and exact age as a continuous covariate.
A Scottish case-control series (UK 1) was examined initially,
consisting of 462 genotyped AMD cases, 52% of whom had
early AMD, and 48% had late AMD (GA or CNV) and 325
examined controls. The rs1683563 SNP was not significantly
associated with AMD (P  0.07). The rs3826945 SNP however
showed evidence of association with AMD, particularly in fe-
males, who showed an odds ratio of 1.70 (95% CI, 1.11–2.63;
P  0.016), although the combined sexes also showed a
significant odds ratio of 1.44 (95% CI, 1.04–2.00; P  0.028)
(Table 2).
TABLE 2. SNP Association Results for CFD SNP rs3826945
Cohort Cases (n) Controls (n) OR 95% CI P Value
UK1
Females 287 182 1.7 1.11–2.63 0.016
Males 175 143 1.22 0.74–2.03 0.432
All 462 325 1.44 1.04–2.00 0.028
UK 2, USA 1, USA 2
Females 1133 576 1.36 1.11–1.68 0.004
Males 779 469 1.07 0.85–1.36 0.571
All 1865 1029 1.23 1.05–1.43 0.01
USA 3, Dutch-German
Females 1409 736 1.03 0.85–1.24 0.801
Males 976 580 1.01 0.82–1.24 0.92
All 2385 1316 1.01 0.88–1.16 0.922
Combined cohorts
Females 2833 1497 1.18 1.04–1.34 0.012
Males 1932 1196 1.04 0.90–1.21 0.57
All 4765 2693 1.11 1.01–1.23 0.032
A dominant model was used to assess the association of the minor allele of rs3826945 to AMD,
controlling for age, sex, and smoking in a total of six cohorts, comprising the discovery cohort, and two
further replication groups. UK 1, UK 2, USA 1, and USA 2 cohorts were also genotyped for rs1683563,
which was not significantly associated with AMD when included as a covariate in the analysis of these
cohorts.
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In view of the low power to reliably detect such a small
effect, we sought to replicate this result by genotyping both
SNPs in a larger case-control set, consisting of an additional UK
series (UK 2) (773 genotyped cases—all with severe AMD—
and 362 examined controls) and two north American series
(USA 1, USA 2). USA 1 (University of Michigan) included 580
genotyped cases (86% severe AMD) and 296 examined controls
while the USA 2 (University of Pennsylvania) series included
512 genotyped cases (100% severe AMD) and 371 examined
controls. The rs1683563 SNP was not significantly associated
with AMD (P  0.89). The results of binary logistic regression
using age, sex, smoking, and the CFD rs3826945 SNP as vari-
ables in 1865 cases and 1029 controls showed a significant
association between AMD and rs3826945, with an odds ratio of
1.23 (95% CI, 1.05–1.43; P  0.01).
A second replication group was then tested, which in-
cluded two further large case-control series, one from USA
(USA 3, Tufts University) and one from Europe (Dutch-German
series). The USA 3 series consisted of 1211 genotyped cases (all
with severe AMD) and 790 examined controls, while the
Dutch-German series consisted of 1174 genotyped cases (68%
with severe AMD) and 526 examined controls. The results of
this analysis of 2385 cases and 1316 controls showed no
evidence of association with rs3826945, because the odds ratio
was 1.01 (0.88–1.16) and P value 0.922. The minor or risk
allele frequency (C allele) for rs3826945 varied from 0.31 to
0.35 in individual case-control series but was very similar in the
UK 1 (0.34), first replication series (0.33) and second replica-
tion series (0.32), so is an unlikely explanation for the apparent
differences between cohorts (Table 1).
We combined all the above results into a single meta-
analysis (4765 cases and 2693 controls), which showed a
significant association overall (OR, 1.11; CI, 1.01–1.23; P 
0.032) between AMD and rs3826945. The odds ratio was sig-
nificant in females (OR, 1.18; 95% CI,1.04–1.34 in females; P
0.012) but not in males (OR, 1.04; 95% CI, 0.90–1.21; P 
0.57). Similar results were obtained using an allelic (additive)
model (data not shown). The results of the meta-analysis are
summarized as a Forest plot in Figure 1 and Table 2. Interac-
tions between smoking and CFD SNP rs3826945, or between
body mass index and rs3826945, did not influence the associ-
ation with AMD in cohorts where these data were available.
The minor allele of rs3826945 was not significantly associ-
ated with either GA or CNV in any of the series analyzed
independently. In the combined series, there was a borderline
significant association between the minor allele and CNV (P 
0.043; OR, 1.154; 95% CI, 1.004–1.325), but not with GA (P 
0.359; OR, 1.089; 95% CI, 0.908–1.306). This analysis included
1681 controls, 660 GA cases, and 1687 CNV cases. Splitting the
combined series by sex, there was no significant association
observed in males (755 controls, 266 GA cases, and 659 CNV
cases), and there was only suggestively significant association
in females (926 controls, 394 GA cases, and 1028 CNV cases).
For GA females, the minor allele P value was 0.098 (OR, 1.223;
95% CI, 0.963–1.552); for CNV females, the P value was 0.056
(OR, 1.196; 95% CI, 0.995–1.437). The GA group is however
much smaller than the CNV group, reducing the power to
detect effects of CFD on these clinical subgroups. Plasma CFD
is therefore significantly elevated in both neovascular and atro-
phic AMD, although it is more significant in neovascular AMD
(but again, there are more cases).
Copy Number Variation in the CFD Gene
Copy number variation in the CFD gene was measured using a
copy number assay (TaqMan; Applied Biosystems), in a duplex
real-time polymerase chain reaction, as described in Materials
and Methods. The relative copy number of CFD was normal-
ized to the known copy number of the RNAseP reference
sequence and calculated using software (Copycaller; Applied
Biosystems) using a conservative CT threshold value of 32
across all plates. Copy number was measured in 311 AMD
cases and 329 controls from the UK 1 (Scottish AMD) case-
control series. Copy number variation in the CFD gene was
identified in 4 out of 311 AMD cases (two with a single copy
and two with three copies) and 9 out of 329 controls (one with
zero copies, five with a single copy, and three with three
copies). There was no significant difference in CFD duplica-
tion/deletion frequency between cases and controls (1.3% of
AMD cases and 2.7% of controls; P  0.51 using Fisher’s exact
test). The results are summarized in Figure 2.
Plasma CFD Concentration in AMD Cases
and Controls
An enzyme-linked immunosorbent assay (ELISA) was devel-
oped to measure plasma CFD concentrations, as described in
Materials and Methods. The plasma CFD concentration was
measured in 751 AMD cases and 474 controls from the UK 1
and UK 2 case-control series and found to be elevated in AMD
cases compared with controls; median plasma CFD concentra-
tion was 2.31  0.043 (SEM) g mL1 in cases and 2.08 
0.046 g mL1 in controls (P  0.00025; Fig. 3). When sam-
ples were broken down by sex, plasma CFD was significantly
greater in AMD females than control females (P  0.0004) but
there was no significant difference between AMD males and
control males (P  0.135). The odds ratio for those of both
sexes in the highest versus lowest quartile of plasma CFD was
1.81 (95% CI, 1.27–2.57; P  0.001), while for the sexes
FIGURE 1. Forest plot summarizing
the results of the meta-analysis of asso-
ciation studies between CFD SNP
rs3826945 and AMD in three United
States AMD case-control series (USA
1–3) and three European case-control
series (UK 1–2, and Dutch-German [Ni-
jmegen]). The result of meta-analysis
showed a significant association in the
combined sexes (OR, 1.11; P 0.032)
and in combined females (OR, 1.18;
P  0.012) but not in males.
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separately, the corresponding odds ratios were 2.15 (95% CI,
1.35–3.44; P  0.001) in females and 1.42 (95% CI, 0.82–2.47;
P  0.215) in males.
There was no association between genotype at rs3826945
and plasma CFD concentration (P  0.309). However, plasma
CFD was found to be elevated in individuals with BMI 30
who had a median plasma concentration of 2.11 0.076 (SEM)
g mL1, compared with BMI25 (median value 1.77 0.064
(SEM) g mL1; P  3  106). When BMI was included as a
covariate in regression analysis for 272 controls and 402 AMD
cases for whom BMI data were available, the odds ratio for the
highest versus lowest quartile of plasma CFD was 2.03 (95% CI,
1.26–3.27; P  0.004).
DISCUSSION
Complement factor D is a unique member of the alternative
complement pathway both in terms of its unusual mode of
activation and its tissue expression profile.1,2 Adipose tissue is
the major source of plasma CFD, which is thought to be
constitutively secreted at a high rate but rapidly catabolized in
tissues such as the kidney.1,4 The fractional catabolic rate of
plasma CFD has been estimated to be 60% per hour,22 contrib-
uting to its low serum concentrations. White adipose tissue is
increasingly regarded as an endocrine organ, secreting a variety
of hormones, such as leptin, as well as immune and inflamma-
tory mediators, such as CFD and tumor necrosis factor-.23,24
Adipose tissue contains several different cell types, the most
abundant being adipocytes, but bone-marrow derived macro-
phages are also recruited in substantial numbers, possibly by
chemokines such as monocyte chemoattractant protein-1
(MCP-1) that are expressed by adipocytes. The liver is the
major source of most complement components found in
plasma, with the notable exceptions of CFD and C1q.25 How-
ever, adipocytes are also able to synthesize many complement
components, particularly those involved in the initial steps of
complement activation via both classical and alternative path-
ways (e.g., factor B, C2, C3, C4, C1Q, C1R, C1S) but they
FIGURE 2. CNV in the CFD gene in
AMD cases and controls showing the
proportion of duplicated and deleted
genes. The difference between AMD
cases and controls was not statisti-
cally significant.
FIGURE 3. ELISA assay of plasma
CFD concentration in AMD and con-
trol subjects in the combined UK 1
and UK 2 series. The difference was
statistically significant both in the
combined sexes (P 0.00025; upper
panel) and in females (P  0.0004)
but not in males.
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express almost none of the terminal complex components (C5,
C8A, C8B, C8G, C9), with the exception of C7.5,26,27 Adi-
pocytes therefore appear to be the major source of plasma CFD
in normal individuals, which is supported by our finding that
median plasma CFD was significantly higher in obese individ-
uals compared with those with a BMI25 (P 0.000003), but
cells in the monocyte/macrophage lineage also contrib-
ute.4,25,26 The situation in individuals with diseases associated
with alternative complement pathway activation, such as AMD,
may not be identical.
The finding that plasma CFD is significantly raised (11%
increase; P  0.00025) in a large sample of AMD cases com-
pared with disease-free controls is potentially important be-
cause it is widely thought to be rate-limiting in activation of the
alternative complement pathway. Scholl et al.28 reported a 33%
increase in plasma CFD in a smaller sample of 112 AMD cases
(92% with severe AMD) compared with 67 controls (P 
0.001). These authors also observed increases in plasma levels
of complement components Ba and C3d, indicating chronic
complement activation, perhaps spilling over into the systemic
circulation from the eye. While Reynolds et al.29 also found
raised complement activation products in plasma, including Bb
and C5a, they found no significant change in plasma CFD in a
sample of 120 AMD cases (all with severe disease) compared
with 60 controls, although odds ratios for plasma CFD were 1.4
and 3.1 respectively in models with and without genetic vari-
ants associated with AMD. The present study has substantially
greater power to detect a small difference in CFD between
cases and controls (751 cases and 474 controls) and therefore
helps to resolve this issue. The majority (82%) of the combined
UK 1 and UK 2 cases had severe AMD (GA or CNV), so disease
severity is unlikely to influence the comparison between stud-
ies. Although BMI appears to be significantly associated with
plasma CFD, BMI alone does not explain the significant asso-
ciation of plasma CFD level with AMD in our data, because
including it as a covariate did not result in loss of the associa-
tion.
The finding of raised plasma CFD in AMD versus controls
begs the question as to the source of raised plasma CFD in
AMD. Nonadipose sources of plasma CFD production reported
to date include circulating monocytes/macrophages, lung,
muscle, synovial tissue, and brain astrocytes.4,25 In the eye,
choroidal cells express CFD at over 10-fold higher levels than
either neural retina or RPE, on the basis of quantitative real-
time PCR (qPCR) analyses.30 All initial components of both the
alternative and classical complement pathways and most of the
complement regulators (CFH, DAF, CFI) are mainly expressed
in the choroid rather than in RPE or neural retina, although the
precise cellular source is unclear. C3 levels in choroid-RPE are
particularly high; approximately 5% of those in adult liver, and
most C3 immunoreactivity is localized to the choriocapillaris.30
In contrast, the terminal complement components are absent
from choroid, RPE and neural retina, suggesting that these are
provided by the blood.30 Candidate choroidal sources of alter-
native complement pathway components such as CFD include
macrophages and the choroidal capillaries adjacent to Bruch’s
membrane.
The possibility that AMD therapy could account for the
observed changes in plasma CFD was considered but we do
not have information on who was currently undergoing anti-
VEGF therapy at the time of sampling. Changes in VEGF can
result from activation of the alternative complement pathway
but we are not aware that the reverse can occur, so there is no
theoretical reason why such treatment would influence our
results.
The colocalization of CFD and its substrates C3 and factor B
in choroidal tissue need not imply local complement activa-
tion, which requires their deposition on a surface in which
they can evade control by CFH, CFI, DAF, MCP, and comple-
ment receptors.31 In AMD, most components of both the
classical and alternative complement pathways and their regu-
lators are deposited between RPE and Bruch’s membrane in
drusen, the hallmark deposits of early-stage AMD.30 CFD depo-
sition is not a feature of drusen, perhaps because of its very low
plasma concentration but raised plasma CFD concentration in
AMD compared with control subjects could reflect a high level
of complement activation occurring in the choriocapillaris-
Bruch’s membrane-RPE region, rather than a systemic disorder
of complement activation.
This is the first report of genetic association between AMD
and variation within the CFD gene. The association is confined
to a single noncoding SNP, rs3826945, within intron 4 of the
CFD gene (chr19:813,912), which spans 3.9 kb on 19p13.3 and
contains five exons. This variant is unlikely to directly influ-
ence CFD activity but is most likely to be in LD with a nearby
functional variant(s). The region is one of high gene density,
high recombination, and relatively low LD (http://hapmap.
ncbi.nlm.nih.gov) perhaps explaining why the association
does not appear to extend far outside the rs3826945 region.
The association was confirmed in a large meta-analysis,
including 4765 predominantly severe AMD cases and 2693
examined controls. The effect size was very small (odds ratio
1.11) and almost confined to females (Table 1, Fig. 1). The sex
difference is unlikely to result from the smaller male sample
size—if this were true, the overall P value for the SNP in
combined males and females (P  0.032) should be more
significant than in females only (P  0.012). The same is true
of the plasma CFD measurements. Multinomial logistic regres-
sion was performed using a custom/stepwise approach to
investigate interaction between rs3826945 and sex. In agree-
ment with the results obtained by regression analysis per-
formed in females only, females appear to be more susceptible
to AMD when they carry the risk allele of rs3826945 with an
odds ratio (OR) for the interaction of 1.304 (95% CI, 1.142–
1.489; P  8.73  105) which was increased from OR 1.236
(95% CI, 1.117–1.367) for females without accounting for
genotype, but not significantly so. Sex differences in the heri-
tability of complex traits are common32 so the sex-specific
nature of the CFD association is both biologically plausible and
interesting in light of the sex-specific changes in plasma CFD,
both involving an effect more or less confined to females. This
could suggest that the CFD SNP association serves to indicate
an as yet unidentified variant regulating plasma CFD levels in
females that is in linkage disequilibrium with rs3826945. No
significant association was found between the CFD SNP
(res3826945) and plasma CFD concentration but our study
almost certainly lacked power to detect such an effect, given
that almost 5000 cases were required to show the genetic
association with AMD. If one or more CFD variant does influ-
ence plasma CFD directly (in females), then a causal effect on
AMD risk, rather than raised plasma CFD being a consequence
of AMD, has to be considered.
BMI does not explain the raised plasma CFD in AMD cases
but if the proposed effect of CFD genotype on AMD is medi-
ated by differences in plasma CFD (both of which are largely
confined to females), it is possible that the observed variability
in replication of the genetic association across case-control
series may have been due to differences in BMI between
populations because BMI data were only available in some
series (UK 2, USA 1, Dutch-German). The lack of a statistically
significant interaction between SNP and BMI argues against
this, although the analysis may again have been underpowered.
Manipulation of plasma CFD concentration or inhibition of
its activation in individuals at high genetic risk of AMD pro-
gression might be therapeutically useful regardless of whether
the plasma CFD association is a cause or a consequence of the
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disease. Further work is therefore required not only to confirm
the genetic association but also to identify candidate regulatory
variants by re-sequencing and functional studies of SNP effects
on CFD expression in adipocytes or macrophages.
Follow-up of our findings, particularly investigating the re-
lationship between rs3826945 and putative regulatory variants
in its vicinity, may have therapeutic implications because of
the important role of CFD in regulation of the alternative
complement pathway. The proposed genetic association be-
tween CFD gene variants and AMD requires further investiga-
tion in large meta-analyses and, if confirmed, adds to the evi-
dence implicating this pathway in AMD pathogenesis.
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